NEW YORK (GenomeWeb News) – Pressure BioSciences said today that it has been awarded an $850,000 Phase II Small Business Innovation Research grant from the National Institutes of Health that it will use to continue development of its pressure cycling technology.
The funds will be provided over a two-year period, and work under the grant is expected to begin this summer. The South Easton, Mass.-based company will be collaborating with researchers at Brigham and Women’s Hospital in Boston.
Pressure BioSciences’ PCT is being developed to extract clinically important protein biomarkers, subcellular molecular complexes, and organelles, such as mitochondria, from cells and tissues. The firm has been working on these applications for the past 18 months under a previous SBIR Phase I grant of $149,000.
“This new grant will allow us to continue our efforts in the development and commercialization of standard, automated, and reproducible PCT-dependent methods for obtaining mitochondria and other organelle preparations,” Alexander Lazarev, Pressure BioSciences’ vice president of R&D, said in a statement.